81 related articles for article (PubMed ID: 21178652)
21. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone-releasing hormone-producing pancreatic neuroendocrine tumor in a multiple endocrine neoplasia type 1 family with an uncommon phenotype.
Sala E; Ferrante E; Verrua E; Malchiodi E; Mantovani G; Filopanti M; Ferrero S; Pietrabissa A; Vanoli A; La Rosa S; Zatelli MC; Beck-Peccoz P; Verga U
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):858-62. PubMed ID: 23542451
[TBL] [Abstract][Full Text] [Related]
24. [Pancreatic endocrine tumors].
Târcoveanu E; Moldovanu R; Georgescu S; Niculescu D; Lupaşcu C; Dimofte G
Chirurgia (Bucur); 2006; 101(2):175-81. PubMed ID: 16752684
[TBL] [Abstract][Full Text] [Related]
25. An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas.
Ozaki H; Kinoshita T; Kosuge T; Yamamoto J; Shimada K; Inoue K; Koyama Y; Mukai K
Cancer; 1996 Jun; 77(11):2240-5. PubMed ID: 8635090
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors.
Song S; Shi R; Li B; Liu Y
Pancreas; 2009 Oct; 38(7):811-4. PubMed ID: 19657309
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
[TBL] [Abstract][Full Text] [Related]
28. Calcitonin immunoreactivity and hypercalcitoninemia in two patients with sporadic, nonfamilial, gastroenteropancreatic neuroendocrine tumors.
McLeod MK; Vinik AI
Surgery; 1992 May; 111(5):484-8. PubMed ID: 1350867
[TBL] [Abstract][Full Text] [Related]
29. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
30. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients.
Nikou GC; Toubanakis C; Nikolaou P; Giannatou E; Marinou K; Safioleas M; Karamanolis D
Hepatogastroenterology; 2005; 52(66):1668-76. PubMed ID: 16334754
[TBL] [Abstract][Full Text] [Related]
31. Surgery in malignant pancreatic neuroendocrine tumors.
Nguyen SQ; Angel LP; Divino CM; Schluender S; Warner RR
J Surg Oncol; 2007 Oct; 96(5):397-403. PubMed ID: 17469119
[TBL] [Abstract][Full Text] [Related]
32. Clinical presentation and comparison of surgical outcome for segmental resection vs. Whipple's procedure for solid pseudopapillary tumor: Report of six new cases & literature review of 321 cases.
Manuballa V; Amin M; Cappell MS
Pancreatology; 2014; 14(1):71-80. PubMed ID: 24555981
[TBL] [Abstract][Full Text] [Related]
33. Carcinoma of the pancreas: resection outcome at the University Hospital Kuala Lumpur.
Shahrudin MD
Int Surg; 1997; 82(3):269-74. PubMed ID: 9372373
[TBL] [Abstract][Full Text] [Related]
34. Extrathyroidal Calcitonin Secreting Tumors: Pancreatic Neuroendocrine Tumors in Patients With Multinodular Goiter: Two Case Reports.
Giannetta E; Gianfrilli D; Pozza C; Lauretta R; Graziadio C; Sbardella E; Baroli A; Caronna R; Chirletti P; Lenzi A; Isidori AM
Medicine (Baltimore); 2016 Jan; 95(3):e2419. PubMed ID: 26817871
[TBL] [Abstract][Full Text] [Related]
35. Surgery for mucin-producing pancreatic tumor.
Yasuda H; Takada T; Amano H; Yoshida M
Hepatogastroenterology; 1998; 45(24):2009-15. PubMed ID: 9951855
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
Nissen NN; Kim AS; Yu R; Wolin EM; Friedman ML; Lo SK; Wachsman AM; Colquhoun SD
Am Surg; 2009 Oct; 75(10):1025-9. PubMed ID: 19886158
[TBL] [Abstract][Full Text] [Related]
37. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors.
Falconi M; Zerbi A; Crippa S; Balzano G; Boninsegna L; Capitanio V; Bassi C; Di Carlo V; Pederzoli P
Ann Surg Oncol; 2010 Jun; 17(6):1621-7. PubMed ID: 20162460
[TBL] [Abstract][Full Text] [Related]
38. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
[TBL] [Abstract][Full Text] [Related]
39. Primary malignant pancreatic neoplasms in children and adolescents: a 20 year experience.
Rojas Y; Warneke CL; Dhamne CA; Tsao K; Nuchtern JG; Lally KP; Vasudevan SA; Hayes-Jordan AA; Cass DL; Herzog CE; Hicks MJ; Kim ES; Austin MT
J Pediatr Surg; 2012 Dec; 47(12):2199-204. PubMed ID: 23217876
[TBL] [Abstract][Full Text] [Related]
40. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
Teh SH; Deveney C; Sheppard BC
Am J Surg; 2007 May; 193(5):610-3; discussion 613. PubMed ID: 17434366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
